Medical experts oppose COVID-19 Ayurveda trials

Medical experts say it is a violation of norms

Updated - July 19, 2020 06:40 pm IST

Published - July 18, 2020 08:12 pm IST - Kozhikode

Medical experts and public health activists have objected to the ongoing clinical trials and claims made by a section of AYUSH practitioners on developing a medicine for COVID-19, pointing out that they violate government norms.

Doctors such as S.P. Kalantri of Mahatma Gandhi Institute of Medical Sciences, Sevagram, Maharashtra and Mumbai-based surgeon Sanjay Nagral have written to the Medical Council of India (MCI) against the conduct of clinical trials by a hospital in Jaipur for the drug ‘Coronil,’ manufactured by Patanjali Ayurveda.

Public health activist K.V. Babu has approached the Union Ministry of AYUSH against the clinical trials of ZingiVir-H, a drug by Kerala-based Pankajakasturi Herbals India Pvt. Ltd.

The letter to MCI said that ‘Coronil’ had been advertised as a cure for COVID-19. “Our primary concern is the scientific basis of the risk-benefit analysis conducted by the Principal Investigator and the Institutional Ethics Committee before permission was granted to conduct clinical trial to evaluate ‘Coronil’ for treatment of mild and moderate patients with COVID-19,” they said.

Airing concerns

“It is a matter of concern that the ethics committee approved the protocol for the study without evaluation of proposed dosage and review of toxicology data in animal models. Representations made by the manufacturer to the AYUSH Ministry make no reference to how the dosage was arrived at. There is no mention of any animal models that were used to compute the adverse effect levels for the dosage regimen. The failure of the committee to conduct a rigorous risk-benefit exercise before authorising the clinical study triggers a number of other violations of good clinical practice,” they claimed.

On the clinical trials by Pankajakasthuri, Dr. Babu, an ophthalmologist, pointed out the advertising of AYUSH drugs violated Section 7 of the Drugs and Magic Remedies Act, 1954, and Sections 33(I) & 33(J)) of the Drugs and Cosmetics Act 1940. The study was yet to be completed and peer reviewed.

He pointed out that those undergoing the trials are aged between 18 and 60 and it is an adjunct therapy, not a standalone one.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.